Answers are grounded in this paper and cite their sources.
PURPOSE: To evaluate the diagnostic value of abdominal ultrasonography after transrectal filling with contrast agent (AU-TFCA) in the local T staging of colon cancer. METHODS: This retrospective study included patients diagnosed with colon cancer at Tianjin Third Central Hospital between April 2022 and July 2023. RESULTS: Eighty-six patients (mean age 68.5 ± 9.5; 49 men) were included. The number of patients in stages T1-T4 based on pathological results was 3, 6, 64, and 13, respectively. Kappa agreement: AU-TFCA versus pathology, T3-4 = 0.585, T4 = 0.793; CECT versus pathology, T3-4 = 0.481, T4 = 0.429. ROC using lesion maximum diameter yielded optimal cutoffs of 3.35 and 4.45. AUC = 0.777 and AUC = 0.807. For detecting T3-4: sensitivity 0.779, specificity 0.778, accuracy 0.779. For T4: sensitivity 0.846, specificity 0.699, accuracy 0.721. CONCLUSIONS: AU-TFCA might have higher sensitivity and specificity in preoperative T staging of colon cancer. AU-TFCA might be a valuable tool for colon cancer preoperative T staging, with a better correlation with pathology for T staging than CECT. Still, results require confirmation due to the small number of early-stage cases and the possibility of selection bias.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: